Meeting
2014 ASCO Annual Meeting
Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis.
Authors
Vivek Narasimhan
Sarcoma Oncology Center, Santa Monica, CA
Vivek Narasimhan , James Hu , Kamalesh Kumar Sankhala , Doris V. Quon , Lawrence Menendez , Lita Fernandez , Victoria S Chua , Sant P. Chawla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10599)
DOI
10.1200/jco.2014.32.15_suppl.10599
Abstract #
10599
Poster Bd #
306
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies.
First Author: Andrew Eugene Hendifar
Poster
2021 ASCO Annual Meeting
Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).
First Author: Steven Attia
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2017 Gastrointestinal Cancers Symposium
Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer.
First Author: Weijia Fang